放化疗联合唑莱膦酸治疗乳腺癌骨转移癌的疗效观察

Clinical observation of chemoradiotherapy combined with zoledronic acid for the patients with bone metastasis in breast cancer

目的:观察放化疗联合唑莱膦酸治疗乳腺癌骨转移癌疼痛的疗效及不良反应。方法:分析我院2006年3月—2007年3月收治的48例采用放化疗联合唑莱膦酸治疗乳腺癌骨转移患者的临床及随访资料。患者均接受了局部骨转移灶30Gy/10f放疗,4周期含蒽环类,紫杉类,长春瑞滨,铂类药物的联合方案化疗及2周期唑莱膦酸治疗。结果:疼痛缓解率:完全缓解(CR):52.08%(25/48),部分缓解(PR)35.42%(17/48),轻度缓解(MR):8.33%(4/48),无效(NR):4.17%(2/48),总有效率(CR+PR)为87.50%(42/48)。骨转移灶控制率:完全缓解(CR):12.50%(6/48),PR(部分缓解):33.33%(16/48),NC(无效):39.58%(19/48),PD(进展):14.58%(7/48)总有效率(CR+PR)为45.83%(22/48)。治疗结束后2个月活动能力改善情况:显效:29.17%(14/48),有效60.42%(29/48),无效10.42%(5/48),总有效率:89.58%(43/48)。结论:放化疗联合唑来膦酸是治疗乳腺癌骨转移的一较为理想的治疗方案。

Objective： To observate the curative effect and adverse effect in treating pain for patients with bone metastasis in breast cancer treated with chemoradiotherapy combining with zoledronic acid. Methods： From Mar 2006 to Mar 2008, 48 patients with bone metastasis in breast cancer were analyzed. All patients were given radiotherap（ 30Gy/10f） for local bone metastases, and 4 cycle chemotherapy（ include anthracycline, paclitaxel, vinorelbine and platinum - based chemotherapy） and 2 cycle zoledronic acid. Results： The pain relief rate： complete response （CR） was 52. 08% （25/48）, partial response （PR） was 35.42% （17/48）, minor response（MR） was 8.33% （4/48） and no response （NR） was 4. 17% （2/48） ; Control rates of bone metastases： the overall response was 45. 83%, CR was 12. 50% （6/48）, PR was 33.33% （16/48） and NC was 39. 58% （ 19/48）, development（PD） was 14. 58% （7/48） ; Activities improve after ending the treatment in 2 months： the overall response was 89. 58% （43/48） and CR was 14 case（29. 17%）, PR was 29 cases（60. 42%） and NR was 5 cases （8.96%）. Conclusions： Chemoradiotherapy combined with zoledronic acid is an effective treatment for Patients with bone metastases in breast cancer.